Role of drug efflux carriers in the healthy and diseased brain

Annals of Neurology

Volumn 60, Issue 5, 2006, Pages 489-498

  Hermann, Dirk M ^a   Kilic, Ertugrul ^a   Spudich, Annett ^a   Krämer, Stefanie D ^b   Wunderli Allenspach, Heidi ^b   Bassetti, Claudio L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOSPORIN; INDINAVIR; NELFINAVIR; NEUROPROTECTIVE AGENT; ONT 093; OXCARBAZEPINE; PACLITAXEL; PHENYTOIN; RIFAMPICIN; SAQUINAVIR; TACROLIMUS; TARIQUIDAR; TRABECTEDIN; VERAPAMIL; ZOSUQUIDAR;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; DOWN REGULATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG TRANSPORT; EPILEPSY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN DISEASES; DIBENZOCYCLOHEPTENES; HIV INFECTIONS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; ORGANIC ANION TRANSPORTERS; PHARMACOKINETICS; QUINOLINES; UP-REGULATION;

EID: 33845300239     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21012     Document Type: Article

References (82)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. The NINDS Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
3. Löscher W. Current Status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002;23:113-118.
4. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-477.
5. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
6. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555-558.
7. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004;16:1-13.
8. Higgins CF, Hiles ID, Salmond GP, et al. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature 1986;323:448-450.
9. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001;33:475-479.
10. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
11. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918-926.
12. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of p-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-237.
13. Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP geneencoded conjugate export pump. Cancer Res 1996;56:988-994.
14. Leslie EM, Ito K, Upadhyaya P, et al. Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 2001;276:27846-27854.
15. Minich T, Riemer J, Schulz JB, et al. The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J Neurochem 2006;97:373-384.
16. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-5910.
17. Stride BD, Grant CE, Loe DW, et al. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 1997;52:344-353.
18. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res 1997;57:5232-5237.
19. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998;58:5130-5136.
20. Gennuso F, Fernetti C, Tirolo C, et al. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc Natl Acad Sci U S A 2004;101:2470-2475.
21. Orlowski S, Martin S, Escargueil A. P-glycoprotein and 'lipid rafts': some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci 2006;63:1038-1059.
22. Vøgelgesang S, Warzok RW, Cascorbi I, et al. The role of p-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2004;1:121-125.
23. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdrla p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
24. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29.
25. Pardridge WM, Golden PL, Kang YS, Bickel U. Brain microvascular and astrocyte localization of p-glycoprotein. J Neurochem 1997;68:1278-1285.
26. Demeule M, Labelle M, Regina A, et al. Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance p-glycoprotein isoforms. Biochem Biophys Res Commun 2001;281:827-834.
27. Soontornmalai A, Vlaming ML, Fritschy JM. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006;138:159-169.
28. Zhang L, Ong WY, Lee T. Induction of p-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999;126:509-516.
29. Seegers U, Potschka H, Löscher W. Transient increase of p-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002;51:257-268.
30. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 2004;311:449-455.
31. Miller DS, Nobmann SN, Gutmann H, et al. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000;58:1357-1367.
32. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129:349-360.
33. de Lange EC. Potential role of ABC transporters as a cellular detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004;56:1793-1809.
34. Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 2004;5:95-108.
35. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004;24:7612-7621.
36. Murakami Y, Takamatsu H, Noda A, et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J Nucl Med 2004;45:1946-1949.
37. Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter p-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003;17:503-505.
38. Felix RA, Barrand MA. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 2002;80:64-72.
39. Zhu HJ, Liu GQ. Glutamate up-regulates p-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci 2004;75:1313-1322.
40. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394.
41. Fromm MF. Importance of p-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-429.
42. Abbott NJ, Khan EU, RoIIinson CM, et al. Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found Symp 2002;243:38-47.
43. Spudich A, Kilk E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 2006;9:487-488.
44. Stewart A, Steiner J, Mellows G, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of p-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-4191.
45. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
46. Sisodiya SM, Lin WR, Squier MV, Thorn M. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:42-43.
47. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
48. Potschka H, Löscher W. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. Neuroreport 2002;13:167-171.
49. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce p-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22:5833-5839.
50. Clinckers R, Smolders I, Meurs A, et al. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 2005;314:725-731.
51. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
52. Regina A, Demeule M, Laplante A, et al. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 2001;20:13-25.
53. Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004;30:415-423.
54. Kemper EM, van Zandbergen AE, Cleypool C, et al. Increased penetration of paclitaxel into the brain by inhibition of p-glycoprotein. Clin Cancer Res 2003;9:2849-2855.
55. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-1318.
56. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004;10:1313-1324.
57. Langford D, Grigorian A, Hurford R, et al. Altered p-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004;63:1038-1047.
58. Jorajuria S, Dereuddre-Bosquet N, Becher F, et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 2004;9:519-528.
59. Kim RB, Fromm MF, Wandel C, et al. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
60. Edwards JE, Brouwer KR, McNamara PJ. GF120918, a p-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 2002;46:2284-2286.
61. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (p-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
62. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005;20:391-414.
63. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-3478.
64. Fellay J, Marzolini C, Meaden ER, et al, Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-36.
65. Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003;17:1696-1698.
66. Garrigues A, Nugier J, Orlowski S, Ezan EA. A high throughput screening microplate test for the interaction of drugs with p-glycoprotein. Anal Biochem 2002;305:106-114.
67. Synold TW, Dussault I, Forman BM. The orphan nuclear recepcor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-590.
68. Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat Med 2001;7:536-537.
69. Bartsevich W, Juliano RL. Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinational libraries. Mol Pharmacol 2000;58:1-10.
70. Xu D, Ye D, Fisher M, Juliano RL. Selective inhibition of p-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther 2002;302:963-971.
71. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol 2004;66:268-275.
72. Pichler A, Zelcer N, Prior JL, et al. In vivo RNA interference-mediated ablation of MDR1 p-glycoprotein. Clin Cancer Res 2005;11:4487-4494.
73. Tarasova NI, Seth R, Tarasov SG, et al. Transmembrane inhibitors of p-glycoprotein, an ABC transporter. J Med Chem 2005;48:3768-3775.
74. Mechetner EB, Robinson IB. Efficient inhibition of p-glycoprotein- mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 1992;89:5824-5828.
75. Pawlak-Roblin C, Tosi PF, Perrin L, et al. Inhibition of multidrug resistance by immunization with synthetic p-glycoprotein-derived peprides. Eur J Cancer 2004;40:606-613.
76. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159-165.
77. Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoptotein inhibitor, XR9576. Clin Cancer Res 2003;9:650-656.
78. Rubin EH, de Alwis DP, Poulsquen J, et al. A phase I trial of a potent p-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002;8:3710-3717.
79. Gerrard G, Payne E, Baker RJ, et al. Clinical effects and p-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 2004;89:782-790.
80. Chi KN, Chia SK, Dixon R, et al. A phase I pharmacokinetic study of the p-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs 2005;23:311-315.
81. 18F-paclitaxel in nonhuman primates. J Nucl Med 2003;44:1330-1339.
82. 11C]verapamil. J Pharmacol Exp Ther 2006;316:647-653.